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Abstract
Xeroderma pigmentosum-variant (XP-V) patients have sun sensitivity and increased skin cancer risk.
Their cells have normal nucleotide excision repair, but have defects in the POLH gene encoding an
error-prone polymerase, DNA polymeraseη (polη). To survey the molecular basis of XP-V
worldwide, we measured polη protein in skin fibroblasts from putative XP-V patients (aged 8–66
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years) from 10 families in North America, Turkey, Israel, Germany, and Korea. Polη was
undetectable in cells from patients in eight families, whereas two showed faint bands. DNA
sequencing identified 10 different POLH mutations. There were two splicing, one nonsense, five
frameshift (3 deletion and 2 insertion), and two missense mutations. Nine of these mutations involved
the catalytic domain. Although affected siblings had similar clinical features, the relation between
the clinical features and the mutations was not clear. POLH mRNA levels were normal or reduced
by 50% in three cell strains with undetectable levels of polη protein, indicating that nonsense-
mediated message decay was limited. We found a wide spectrum of mutations in the POLH gene
among XP-V patients in different countries, suggesting that many of these mutations arose
independently.
INTRODUCTION
To maintain DNA integrity, cells have multiple pathways to repair DNA damage caused by
environmental agents. The failure of these systems leads to human disease. Xeroderma
pigmentosum (XP) is an autosomal recessive disorder with an extremely high sensitivity to
UV radiation, leading to a 1,000-fold increase in the incidence of sunlight-induced skin cancer,
caused by defective DNA repair (Kraemer et al., 1987, 1994, 2007; Bootsma et al., 2002;
Kraemer, 2003; Friedberg et al., 2006).
Genetic studies on cultured cells from XP patients revealed seven complementation groups,
XP-A through XP-G, as well as a variant (XP-V) (OMIM no. 278750). The cells from XP-A
through XP-G are defective in nucleotide-excision repair, which is responsible for the removal
of UV-induced damage in genomic DNA (Van Steeg and Kraemer, 1999; Friedberg et al.,
2006). Although different complementation groups exhibit diverse clinical features, these XP
patients generally have early onset of skin cancers and about 20% (XP-A, XP-B, XP-G, and
XP-D) exhibit neurological abnormalities (Rapin et al., 2000; Kraemer, 2003; Kraemer et al.,
2007). In contrast, XP-V, which has been estimated to comprise approximately 20% of XP
patients (Moriwaki and Kraemer, 2001), may have mild or severe clinical features, including
late onset of skin cancers, but rarely have neurological abnormalities.
XP-V cells possess proficient nucleotide-excision repair (Cleaver, 1972; Robbins et al.,
1974, 1975; Broughton et al., 2002; Tanioka et al., 2007), but display exaggerated delay in
recovery of replicative DNA synthesis in association with defective post-replication repair
(Lehmann et al., 1975; Itoh et al., 1996). XP-V cells are hypersensitive to killing by UV
irradiation in the presence of caffeine (Arlett et al., 1975; Maher et al., 1976a; Broughton et
al., 2002), are hypermutable after UV (Maher et al., 1976b; Wang et al., 1993), and have post-
UV plasmid hypermutability in a host cell reactivation assay (Waters et al., 1993).
Extracts from XP-V cells are deficient in the ability to bypass a thymine–thymine cyclobutane
pyrimidine dimer in a DNA replication assay (Svoboda et al., 1998). XP-V cells are unable to
synthesize intact daughter DNA strands on UV-irradiated templates resulting from an inability
to carry out translesion synthesis, the synthesis of DNA directly past damaged sites (Cordonnier
et al., 1999). In 1999, the XPV gene was cloned and found to be POLH (OMIM *603968)
(Johnson et al., 1999a; Masutani et al., 1999b), a human homolog of the yeast RAD30 gene
(McDonald et al., 1997). This gene encodes DNA polymeraseη (polη) and is a member of the
Y-family of DNA polymerases (Ohmori et al., 2001; Yang and Woodgate, 2007) related in
structure to each other, but unrelated to classical DNA polymerases. The POLH gene is located
on chromosome 6p21.1–6p12.3 spanning 40 kb and the calculated relative molecular mass
(Mr) of POLH is 78.4 kDa. The messenger RNA size is of 3,464 bp (GenBank reference number
NM_006502), but the size of the open reading frame is 2,139 bp as the first methionine is
located in exon 2 (Johnson et al., 1999a; Masutani et al., 1999b; Yuasa et al., 2000). The
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function of polη in the error-free bypass of UV-induced DNA lesions has been well
characterized (Johnson et al., 1999b; Masutani et al., 1999a, 2000). However, polη can also
function as a highly mutagenic DNA polymerase when it replicates undamaged DNA, and it
has an important role in generating immune diversity (Zeng et al., 2001; Yavuz et al., 2002).
Previous reports provided information about the molecular defects in XP-V patients from the
United States, Europe, and Japan (Johnson et al., 1999a; Masutani et al., 1999b; Itoh et al.,
2000a; Itoh and Linn, 2001; Broughton et al., 2002; Gratchev et al., 2003; Tanioka et al.,
2007). The causative mutations reported in the POLH gene generally resulted in severe
truncations of the protein and are effectively null alleles. We surveyed POLH mutations in XP-
V patients from different parts of the world in order to assess the origin of this disorder and to
attempt to correlate clinical features with molecular defects. We studied cells from 15 XP-V
patients in 10 families from the United States, the Cayman Islands, Turkey, Israel, Germany,
and Korea. We measured the polη protein levels and determined the causative mutations in the
POLH gene.
RESULTS
Characteristics of XP-V patients and cells
We evaluated 15 putative XP-V patients in 10 families from the United States, the Cayman
Islands, Turkey, Germany, Israel, and Korea (Table 1; Figure 1). XP31BE, a 60-year-old man
in family A from the United States (Figure 1a), had multiple basal cell carcinomas (BCCs),
squamous cell carcinomas (SCCs), and melanomas. As a teenager, the cancer-containing skin
of his face was removed and replaced with sun-protected skin from his trunk. This grafted skin
has remained cancer-free for more than 40 years to the present time. Unscheduled DNA
synthesis (UDS) of his cells was normal. His fibroblasts had normal post-UV plasmid host cell
reactivation, at least 10 times higher than XP-C cells (XP108DC) in this assay (Figure 2). These
are typical features of XP-V cells (Arlett et al., 1975;Maher et al., 1976a;Waters et al.,
1993;Itoh et al., 1996,2000a;Broughton et al., 2002;Friedberg et al., 2006). XP1SE, a 66-year-
old Korean woman in family B, had more than 10 BCCs and SCCs during the past 20 years
(Kim and Chung, 2003). Her cells had normal host cell reactivation (data not shown).
Family C from Turkey had three affected siblings, XP71TMA, an 8-year-old boy with SCC
and BCC (Figure 1b); XP70TMA, a 17-year-old girl with SCC and BCC (Figure 1c); and
XP98TMA, a 26-year-old sister with SCC of her cheek (Figure 1d). Their parents are distant
cousins. The cultured fibroblasts from patient XP70TMA showed normal post-UV UDS and
post-UV plasmid host cell reactivation (Figure 2). XP91TMA, a 10-year-old boy in family D
from Turkey was cancer free (Figure 1e). His elder brother, XP92TMA, died at 22 years of
age from an SCC originating on his lower lip (Figure 1f). His cells had normal host cell
reactivation (Figure 2). Their parents are known to be related to each other. However, families
C and D lived in eastern Turkey, but were not known to be related.
XP38BE in family E from the Cayman Islands had a conjunctival SCC at the age of 8 years.
UDS was 114% and host cell reactivation was normal (Figure 2). XP39BE, his affected sister,
had seven BCCs by age 18. They are of mixed English/African heritage. In family F, two adult
sisters, XP161BE (Figure 1g) and XP164BE (Figure 1h), from the United States, had similar
clinical features. Both had BCC and melanoma, whereas XP164BE also had SCC. Their
cultured cells showed normal-to-mild UV sensitivity, with post-UV hypersensitivity after
caffeine treatment (Table 1). Cells from XP164BE had normal post-UV host cell reactivation
(Figure 2).
XP3GO, a 38-year-old man in family G from Germany, had 12 primary melanoma, 3 SCCs,
and 7 BCCs in the past 16 years (Figure 1i). His cultured skin fibroblasts had post-UV
Inui et al. Page 3
J Invest Dermatol. Author manuscript; available in PMC 2008 October 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
hypersensitivity after caffeine treatment (Table 1) and normal host cell reactivation (Figure 2).
XP139DC, a 19-year-old man from the United States in family H, had a BCC. His cells showed
normal UDS and normal host cell reactivation (data not shown). The cells had post-UV
hypersensitivity to killing after caffeine treatment (Table 1).
XP224BE, a 31-year-old Caucasian woman in family I from the United States, had BCC and
SCC (Figure 1j). Her cultured cells had normal host cell reactivation (Figure 2). XP10TA, a
53-year-old Iraqi–Israeli woman in family J, had two melanomas. Her parents were first
cousins. Her cells had normal host cell reactivation (Figure 2).
The patients we examined in families A, B, C, D, F, G, I, and J had no XP-type neurological
abnormalities (Rapin et al., 2000) and none were reported for the other patients by the referring
doctors. These patients did not have loss of vision due to corneal clouding. They showed a
range of cutaneous involvement and all showed freckling at an early age. The patients in
families C and D had marked progression of pigmentary changes along with atrophy and
telangiectasia. However, in the others these changes remained limited despite development of
skin cancers. Their skin is similar in appearance to chronic sun damage in fair-skinned
individuals in the general population.
Semi-quantification of polη protein expression
We used an immunoprecipitation (IP) procedure for detecting polη protein using monoclonal
and polyclonal antibodies (Thakur et al., 2001; Laposa et al., 2003; Tanioka et al., 2007) in
extracts from primary cells. As shown in Figure 3a, normal fibroblast whole-cell extracts (lanes
1, 2, 6, 7, 12, and 16) have a dark band of polη protein, with an estimated size, which is
coincident with the expected size of 78.4 kDa. In contrast, cell lines XP224BE (lane 5) and
XP10TA (lane 11) show faint bands, whereas the other XP-V cells (Figure 3a, lanes 3, 4, 8, 9,
10, 13, 15, 17, and 18) show undetectable levels of polη protein. Similarly, protein extracted
from normal lymphoblastoid cells (AG10107 and AG10033) showed an intense band at the
expected size and lymphoblastoid cells from XP31BE had an undetectable level of polη protein
(data not shown). This assay demonstrates the large difference in levels of polη protein between
normal and XP-V cells (Table 2).
Mutation analysis
Sequencing of entire POLH coding region and exon/intron junctions were carried out for exon
2 through exon 11. The causative mutations were identified in all 10 cell lines. The mutations
and the predicted proteins encoded by the mutant alleles are summarized in Table 2. Virtually
all of the mutations were located in regions that are likely to affect the catalytic core of the
enzyme. The exception was patient XP139DC, who had a mutation in one allele of exon 11 of
POLH, encoding the C-terminus of polη (see below). Of the previously reported mutations in
POLH that give rise to XP-V, only 6 out of 60 (including those described here) have been found
in exon 11 (Johnson et al., 1999a;Masutani et al., 1999b;Itoh et al., 2000b;Itoh and Linn,
2001;Broughton et al., 2002;Gratchev et al., 2003;Tanioka et al., 2007), suggesting that
mutations in this region may give rise to mild phenotypes that may be difficult to diagnose
clinically as XP-V.
POLH splice donor site mutations in XP31BE and XP1SE
Sequencing XP31BE genomic DNA from family A revealed a mutation in the exon 6 splice
donor site, G-to-C transversion (c.764+1G>C) (Figure 4a). The sequence at this exon–intron
junction represents a strong donor site in the normal sequence and the single base substitution
in XP31BE reduced its information content from 9.3 bits to −0.5 bits (Schneider, 1997a, b;
Table S2). To confirm whether this splice donor site mutation results in alteration of POLH
mRNA splicing, we performed reverse transcriptase-PCR (RT-PCR) surrounding exon 6, using
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two primers, a forward primer (c504F) in exon 5 and a reverse primer (c892R) in exon 8/7
junction using RNA from the XP31BE and a control (Figure 4b). RT-PCR showed that normal
cells had a single band of the expected size. In contrast, XP31BE had two shorter bands.
Sequencing of these two bands revealed two splice variants of POLH mRNA. Type I splice
form, with the greater expression, has a deletion of the entire exon 6 (104 bp) (r.661_764del104)
(Table 2). This out-of-frame deletion is expected to produce a 221-amino-acid truncated protein
(p.Val221Profs*2). Type II splice form uses a cryptic splice donor site, 42 bp upstream from
the end of exon 6, which has an information content of 3.8 bits (Table S2). The resulting in-
frame deletion (r.723_764del42; p.ser242_Ile255del14) leads to shortening of the polη protein
by 14 amino acids (Table 2). We examined inheritance of the mutation in family A by using
PCR-restriction-fragment length polymorphism (RFLP) (Figure 4c). The G-to-C transversion
creates a new DdeI restriction site, which cuts the mutant genomic DNA into two fragments.
DdeI-treated DNA from the mother of XP31BE shows one normal band as well as the shorter
bands, indicating that she is heterozygous for this mutation. However, DdeI-treated DNA from
the XP31BE patient shows only the shorter bands. DdeI-treated DNA from the father does not
show cutting by this enzyme, indicating that the G-to-C mutation is absent. But the genomic
DNA sequence from the patient shows only the mutated base (C) without the correct base (G),
indicating that he did not receive the correct base from either parent at this site (Figure 4a).
Thus, we assume that this region of the DNA from his father is deleted. Hence, the XP31BE
patient is hemizygous for this splicing mutation (Table 2).
XP1SE in family B had a homozygous splice donor mutation in exon 4 (c.490 G>T) (Table
2). This mutation reduced the information content of the splice donor site from 5.4 to 2.1 bits
(Table S2). We found two alternatively spliced isoforms (r.401_490 del90 and r.490+163)
resulting in proteins of 683 (p.Gly134_Lys163del30) and 191 amino acids
(p.Glu164Glyfs*29), respectively, using cryptic donor sites within exon 4 (6.1 bits) and within
intron 4 (6.5 bits) (Table S2). This same homozygous mutation was reported in six XP-V
patients from Japan (Tanioka et al., 2007). Many Japanese XP-A patients have a splice
mutation, which has been identified as a founder mutation carried by about 1% of the Japanese
general population (Hirai et al., 2006). Possibly this POLH splice mutation in Japan and Korea
is also a founder mutation.
Nonsense mutation in families C and D
XP70TMA in family C and XP92TMA in family D have the same mutation in exon 4. This
G-to-C transversion at position 454 (Table 2) resulted in a nonsense mutation (p.Gln152*).
The predicted protein size is 151 amino acids. This mutation creates a DdeI restriction site
(Figure 5). The digested DNA from the mother of family C (XPH95TMA) shows three bands
indicating that she was heterozygous for this mutation. The DNA from the affected siblings in
both families showed complete digestion, indicating that the mutation is homozygous. This is
consistent with the clinical history of consanguinity in each of these families.
There is no history of a common relative linking family C and family D. These families both
live in eastern Turkey. Both of these XP-V families have multiple affected children (Figure 1,
C-1, C-2, C-3, D-1, and D-2) and some of them have developed skin cancer at an early age.
An earlier study of the inheritance of the XPC gene in a family from this region of Turkey
examined microsatellite markers and found a genetic link to another XP-C family in Italy with
a common ancestor about 300–500 years ago (Gozukara et al., 2001). Similar studies of
microsatellites or single-nucleotide polymorphisms might indicate the extent of relationship
between these families.
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Truncation in the catalytic domain of POLH
The cells from patients in families E and F had the same mutation. Insertion of a single G at
1078 in exon 10 was identified in XP38BE (c.1078_1079dupG) (Figure 6a) and XP161BE
(data not shown). This uncloned genomic DNA sequence does not show double bands, thus
indicating that both alleles have the same insertion or that one allele has the mutation and the
other allele is absent. This frameshift mutation codes for 31 unrelated amino acids before a
termination codon at codon 391 (p.Asp360Glyfs*32) (Table 2). The mutation creates a new
BslI site. Digestion of DNA from XPH253BE, the mother of family E (Figure 6b), produces
three bands, indicating that she is heterozygous for this mutation. DNA from the affected
siblings XP38BE and XP39BE is completely digested (Figure 6b), indicating that they are
homozygous or hemizygous for this mutation, as suggested from the sequence tracing (Figure
6a). DNA from the father was not available for testing. PCR-RFLP analysis of DNA from
family F (Figure 6c) shows complete digestion of the DNA from both affected sisters XP164BE
and XP161BE. Digested DNA from both parents yields three bands, indicating that they are
heterozygous for this mutation. Thus, we can conclude that the patients are homozygous (and
not hemizygous) for this mutation. As expected, the children of patient XP161BE are
heterozygous for this mutation (Figure 6c). Family E is from the Cayman Islands and family
F from the United States. We have no history of consanguinity between these families. This
mutation was also reported (Johnson et al., 1999a) in XPPHBE, a 30-year-old Caucasian man
who has an affected brother, XP13BE (Robbins et al., 1974; Moshell et al., 1981).
XP3GO cells in family G had a 1-kb deletion (g.24139_25203del1065) in the genomic DNA
that includes exon 6 (Table 2). This homozygous deletion is predicted to result in a truncated
protein of 221 amino acids (p.Val221-Profs*2). Mutated cDNA with this sequence was
reported previously (Johnson et al., 1999a) in cell line XP5MA from an 86-year-old woman
from Germany with “pigmented xerodermoid” (Hofmann et al., 1978). The mutation in the
genomic DNA of XP5MA was not reported. Interestingly, the deletion of exon 6 was also seen
in the type-I splice isoform in the cells from XP31BE who has a splice mutation (Table 2;
Figure 4b).
XP139DC cells in family H had two different frameshift mutations (Table 2). Deletion of the
170 bases of exon 10 (c.1075_1244del170) resulted in an altered protein beginning at Asn359
and terminating after 389 amino acids (p.Asn359-Valfs*32). This same mutation was reported
as homozygous at the cDNA level in XP6VI and XP75VI cells (Broughton et al., 2002). The
other mutation in XP139DC cells was a 2 bp deletion in exon 11 (c.1706_1707del2). This
would result in a truncated 577-amino-acid protein (p.Thr569Argfs*10).
XP224BE in family I is a compound heterozygote for a frameshift mutation and a missense
mutation (Table 2). One allele has an insertion of a single T at nucleotide 149 in exon 3 (c.
149_150dupT). This frameshift mutation creates a new termination signal 3 codons
downstream, resulting in a truncated 52-amino-acid protein (p.ser51Glufs*3). This
heterozygous mutation was identified in cells from her father (XPH227BE) (data not shown).
The +T149 insertion inactivates a BtsI restriction site. A PCR-RFLP assay using BtsI confirmed
that DNA from the patient, XP224BE, and her father, XPH227BE, were heterozygous for this
mutation, and that DNA from her mother’s cells, XPH226BE, was not digested, indicating a
normal sequence (data not shown).
Missense mutations
The second allele of XP224BE carried a transition mutation of A to G (c.658A>G) in exon 5
(Table 2). This missense mutation changed lysine 220 (AAG) to glutamate (GAG)
(p.Lys220Glu), but preserved the size of the protein. This heterozygous mutation was also
present in cells from her mother (XPH226BE) (data not shown). To determine if the POLH c.
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658A>G mutation was a common polymorphism, we screened DNA obtained from buccal
swabs of 100 anonymous donors (Khan et al., 2000). DNA sequence analysis showed the
normal A/A genotype for all 100 donors, indicating that the POLH c.658A>G mutation was
not a common polymorphism (data not shown).
The mutation of XP10TA in family J was homozygous for a missense mutation in exon 5 based
on the DNA sequence analysis and the family history of consanguinity (Table 2). This mutation
(c.522 G>T), which changes tryptophan 174 to cystine (p.Trp174Cys), may affect protein
conformation because of the conversion from a hydrophobic amino acid to a hydrophilic amino
acid in the catalytic domain of POLH. We determined that c.522G>T was not a common
polymorphism by screening 100 DNA samples from normal donors (Khan et al., 2000) using
PCR-RFLP analysis with BsmAI. All of the donors’ samples had the restriction pattern of the
normal G/G genotype (data not shown).
POLH mRNA in XP-V cells
Western blotting (Figure 3) and sequence analysis (Table 2) indicated that polη protein was
not detectable in the mutant cells that yielded premature terminations, and a faint band could
be seen in the mutants that had missense mutations. One mechanism for the observed large
reduction in polη protein would be nonsense mediated message decay (Kuzmiak and Maquat,
2006). Nonsense-mediated message decay has been observed in cells from XPC patients who
have mutations leading to premature stop codons (Khan et al., 2006). We measured POLH
mRNA levels (Table 3; Table S1) in XP-V cell lines that had no detectible polη protein (Figure
3) resulting from a splice site mutation (XP31BE), a frameshift mutation (XP38BE), or a
nonsense mutation (XP70TMA) (Table 2). Three normal fibroblast strains had a mean of 77.2
fg of full-length message (exon 1/exon 2 boundary primer), 81.9 fg (exon 2/exon 3 boundary
primer), and 3 fg of POLH mRNA (exon 2-skipping primers) (Table 3). The cell strains with
splicing and frameshift mutations had normal levels of POLH mRNA (Table 3), demonstrating
absence of nonsense-mediated message decay in these cells. The cell strain with a nonsense
mutation (XP70TMA) had POLH mRNA levels that were about half of normal (Table 3),
demonstrating nonsense-mediated message decay in these cells. All of the cell strains had
normal levels of skipping of exon 2 in POLH mRNA.
Polι in XP-V cells
DNA polymeraseι (polι) is another Y-family DNA polymerase (Woodgate, 1999; Ohmori et
al., 2001; Kannouche et al., 2003) that was recently identified as playing a role in
carcinogenesis in cells lacking polη (Wang et al., 2007). We measured the level of polι protein
in XP-V cells with undetectable or with very low levels of polη (Figure 3b). All of the cells
examined had levels of polι protein in the normal range (Figure 3b, and data not shown).
DISCUSSION
Laboratory identification of XP-V cells
XP-V classically has been defined by the combination of the clinical features of XP with normal
post-UV cell survival that is reduced by caffeine, normal post-UV UDS and reduced post-UV
DNA synthesis (Itoh et al., 1996). These conventional laboratory examinations separate XP-
V from normal cells, but they cannot identify the molecular defect in XP-V cells. The
identification of the POLH gene has greatly facilitated molecular diagnosis of XP-V. IP-
western blotting was able to detect POLH protein in nuclear extracts from simian virus-
transformed cells (Thakur et al., 2001; Laposa et al., 2003). In this procedure, POLH protein
from SV-transformed normal cells showed a dark band at 78 kDa, whereas POLH protein in
XP-V SV-transformed cells (XP30RO) was not detected. The monoclonal antibody for polη
recognized the 300 amino acids at the C-terminal end of polη protein. XP30RO cells, with a
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13-base deletion in exon 2, generate a severely truncated protein, which deletes the recognition
site of the antibody. We have simplified this assay permitting use of whole-cell extracts,
simplified IP, and measurement of protein concentration by a standard protocol. The simplified
method detects polη levels in primary fibroblasts (Figure 3; Tanioka et al., 2007) and
lymphoblastoid cells.
Undetectable polη protein: nonsense-mediated message decay and post-translational
degradation
One mechanism for the observed large reduction in polη protein would be nonsense-mediated
message decay (Kuzmiak and Maquat, 2006). For example, nonsense-mediated message decay
has been observed in cells from XP-C patients who have mutations leading to premature stop
codons (Khan et al., 2006). An XP-V cell strain (XP70TMA) with a nonsense mutation in the
POLH gene (Table 2) had no detectable polη protein levels (Figure 3) and showed about 50%
of normal POLH mRNA levels (Table 3). This reduction in mRNA level may be due to
nonsense-mediated message decay; however, the level of reduction of mRNA is less than seen
in XP-C cells with nonsense mutations (reduced to <25% of normal) (Khan et al., 2006).
Northern blots from XP-V cells showed different levels of poly(A)+ RNA ranging from
undetectable to normal levels in different cells with nonsense or frameshift mutations
(Masutani et al., 1999b). We found normal levels of POLH mRNA in XP-V cell strains with
no detectable polη protein and splice (XP31BE) or frameshift (XP38BE) mutations (Table 3).
Thus, these cells have no evidence of nonsense-mediated message decay. The low polη protein
levels may be caused by increased proteolysis mediated via ubiquitin binding, as demonstrated
in studies of polη (Bienko et al., 2005) or its yeast homologue, RAD30 (Skoneczna et al.,
2007).
Trace protein levels: missense mutations with alteration of RNA processing and protein
degradation
XP10TA and XP224BE(2) have missense mutations in the catalytic domain, and western
blotting showed faint bands of polη protein (Table 2; Figure 3a). XP10TA has a homozygous
base substitution mutation in exon 5 that results in a missense mutation Trp174Cys. The c.522
G>T mutation increases the strength of a cryptic RNA splice acceptor (Schneider, 1997a,b)
within exon 5 from 8.8 to 10.2 bits (data not shown). This mutation within an exon may result
in altered RNA splicing as reported in cells from patients with isovaleric acidemia (Vockley
et al., 2000), with accompanying low levels of protein. Similarly, the heterozygous c.658 A>G
base substitution mutation in exon 5 in XP224BE reduces the information content of the donor
from 7.8 to 6.8 bits (Table 3, and data not shown), possibly reducing the extent of normal
splicing leading to low levels of polymeraseη protein.
Alternatively, the missense mutation may alter the stability of the protein as described for XPC
(Yasuda et al., 2007) or for Escherichia coli umuC, the bacterial equivalent of polη (Woodgate
et al., 1994). The two missense mutations, tryptophan (hydrophobic amino acid) 174 to cysteine
(hydrophilic amino acid) in XP10TA and lysine (basic amino acid) 220 to glutamate (acidic
amino acid) in XP224BE, may influence the polη protein conformation, resulting in instability
or structure change at the epitope of antibody binding. One cell line, XP11BR, with a missense
mutation in the catalytic domain, has been reported to be defective in translesion synthesis
activity (Broughton et al., 2002). This glycine 263-to-valine alteration leads to the conversion
from a hydrophilic amino acid to a hydrophobic amino acid.
Mutation spectrum and predicted POLH protein function
Following results of IP-western blotting, we sequenced eight cell lines, which have no band
of polη protein and two cell lines with a faint band. We found 10 different mutations in 10
patients. These mutations were classified as splicing, frameshift, nonsense, and missense
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(Table 2). The functional structure of pol-η protein has been elucidated (Figure 7; Johnson et
al., 1999a;Masutani et al., 1999b;Yamada et al., 2000;Kannouche et al., 2001,2003;Ling et
al., 2001,2003;Broughton et al., 2002;Bomar et al., 2007;Yang and Woodgate, 2007). The N-
terminal 400 amino acids are highly conserved in the Y-family polymerases (Boudsocq et
al., 2002). The polymerase activities of polη reside entirely in the first 511 amino acids of the
713-amino-acid protein (Masutani et al., 1999a). The C-terminal 200-amino-acid region does
not have polymerase function, but contains a bipartate nuclear localization signal between
residues 682–698 and the C-terminal. The C-terminal 120 amino acids of polη are sufficient
for nuclear localization, and for localization into foci (Kannouche et al., 2001). Cell-free
extracts from XP-V with severe truncation in the catalytic domain were shown to be defective
in translesion synthesis activity. This suggests that mutant alleles with truncations between 52
and 390 amino acids in our patients’ cells (XP31BE, XP3GO, XP38BE, XP161BE, XP70TMA,
XP92TMA, XP224BE(1), and XP1SE variant II) would have defective polymerase activity.
Splice variant II of XP31BE has a 13-amino-acid in-frame deletion in exon 6. XP3DU with
in-frame deletion in exon 3 also has defective bypass ability in a translesion synthesis assay
(Broughton et al., 2002). This suggests that mutations found in the patients’ cell lines with
undetectable or faint bands of polη protein in western blotting are causative for XP-V.
Splicing abnormalities
Information theory is an important tool to rank normal and mutant splice junctions, and most
splice junctions that are fully functional have an information content of at least 2.4 bits
(Schneider, 1997a, 1997b; Rogan et al., 1998). Splice-site mutations may result in exon
skipping, activation of cryptic splice sites, creation of a pseudo-exon within intron, or intron
retention. The splice donor at exon 6 in normal sequence has an information content of 9.3 bits
(Table S2). The exon 6 splice donor site mutation in XP31BE inactivates the normal splice
donor, resulting in two splice variants, one of which results from skipping of exon 6 and the
other from activation of a cryptic splice site in exon 6 (Figures 4 and 7). Another XP-V cell
(XP1RO) had a splice acceptor site mutation in exon 2 (Masutani et al., 1999b). This mutation
also reduced information content at the splice acceptor from 3.4 to <0 bits, and led to skipping
of exon 2. XP1SE has a mutation within exon 4, which reduces the splice donor site information
from 5.4 bits to 2.1 bits.
Origin, inheritance, and clinical features of XP-V mutations in different parts of the world
Some DNA-repair genes also function as basal transcription factors and are thus essential for
survival. Complete inactivation of both alleles of these genes is not compatible with life. Thus,
mutations in affected patients must preserve some genetic activity and hence only a limited set
of mutations would be observed in at least one allele. An example of this is the XPD gene
where unrelated patients from many different countries have mutations at the same site
(R683W) (Taylor et al., 1997; Lehmann, 2003; Friedberg et al., 2006). This mutation has been
shown to retain some activity (Dubaele et al., 2003). In contrast, the XPC gene is not essential
for life and can be completely inactivated with undetectable levels of XPC protein (Khan et
al., 2006). In the XPC gene, many different mutations have been found without an accumulation
at one site (Chavanne et al., 2000; Gozukara et al., 2001; Friedberg et al., 2006; Khan et al.,
2006).
The XP-V gene appears to be closer to the model of a nonessential gene, with no one site having
a preponderance of mutations (Johnson et al., 1999a; Broughton et al., 2002; Tanioka et al.,
2007) and undetectable levels of polη protein (Figure 3). We found 10 mutations in POLH in
10 families. Two families from Turkey (families C and D) had the same homozygous nonsense
mutation, whereas two families from North America (families E and F) had the same
homozygous frameshift mutation. A patient from Korea had the same probable founder
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mutation as that in Japanese XP-V patients (Tanioka et al., 2007). The other five families had
seven different mutations. These probably arose independently.
The 15 XP-V patients we studied had a range of clinical features (Table 1). None had XP related
neurological abnormalities (Rapin et al., 2000;Kraemer et al., 2007) or loss of vision due to
corneal clouding. They all developed freckles at an early age. In some of the patients, this did
not progress (for example, XP224BE and XP10TA) and their skin looked similar to that of
chronic sun damage in fair-skinned individuals in the general population. While in others, for
example, in patients from Turkey (families C and D) (Figure 1), the skin changes resulted in
extensive cutaneous pigmentation and atrophy. All of the patients, except for two of the
youngest, had skin cancer and six had melanoma. This is similar to the average age of reported
skin cancer in more than 800 XP patients of less than 10 years (Kraemer et al., 1987,1994).
The group includes four (27%) XP-V patients older than 45 years (Table 1). This is a relatively
old age for XP patients compared with the 5% of 785 reported XP patients who were older
than 45 years (Kraemer et al., 1987), and may reflect a tendency of XP-V patients to live longer
than XP patients with defects in nucleotide-excision repair genes. However, one XP-V patient,
XP92TMA (Table 1;Figure 1, D-2) died of metastatic SCC of his lip at 22 years of age. Our
first XP-V patient, XP4BE, had ocular involvement, extensive cutaneous changes, more than
100 skin cancers, and died at 27 years of metastatic melanoma (Robbins et al., 1974,1975).
A correlation between the clinical features and the different POLH mutations is not clear (see
also Tanioka et al., 2007). Cells from the two patients with missense mutations (XP24BE and
XP10TA) showed trace polη protein on the western blots (Figure 3), and were from adults
without marked progression of their pigmentary abnormalities. The patients with extensive
cutaneous pigmentation and atrophy (families C and D) had a homozygous nonsense mutation
that resulted in no detectible polη protein (Figure 3). However, other patients with absent
polη protein did not show these extensive cutaneous changes.
XP and polι protein
We also examined the level of polη protein in 16 cell strains from other suspected UV-sensitive,
cancer-prone XP-V patients who were referred to the authors. We found them to have normal
post-UV cell survival, host cell reactivation, or DNA repair (data not shown). However, unlike
true XP-V cells, these cells had normal levels of polη protein and we were unable to detect any
mutations in POLH (data not shown). We therefore considered the possibility that these clinical
phenotypes may have arisen because of mutations in another polymerase involved in the
translesion synthesis of UV photoproducts. A good candidate enzyme appeared to be polι,
which is a paralog of polη (Ohmori et al., 2001). Polι has also been shown to physically interact
with polη, and both polymerases colocalize to sites of UV-induced DNA damage (Kannouche
et al., 2002). Furthermore, polι can bypass cyclobutane dimers in vitro (Vaisman et al.,
2003; Frank and Woodgate, 2007) and mice lacking polι exhibit mild sensitivity to UV-light
(Dumstorf et al., 2006). We therefore measured the level of polι protein in these cells, as well
as sequenced the entire POLI gene. However, all cells exhibited normal levels of polι protein
and did not contain any mutations in POLI (data not shown). The molecular defects causing
the phenotype resembling XP-V in these cells therefore remain to be determined.
MATERIALS AND METHODS
Patients and cells
Patients were examined in accordance with the Institutional Review Boards at their institutions
(National Institutes of Health, Bethesda, MD; Yüzüncü Yil University Medical School, Van,
Turkey; Wuerzburg University, Wurzburg, Germany; Armed Forces Institute of Pathology,
Washington, DC; Yonsei University College of Medicine, Seoul, Korea; and Tel Aviv
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University, Tel Aviv, Israel) or their cells were obtained from the Human Genetic Mutant Cell
Repository, Camden, NJ. The studies followed the Declaration of Helsinki Principles and
patients gave informed consent for these studies. The cell lines examined in this study are listed
in Table 1. Patients’ skin primary fibroblasts (XP31BE (GM13155), XP38BE (AG02592),
XP70TMA (GM14873), XP92TMA (GM15713), XP224BE (GM16818), and lymphoblastoid
cell lines (XP31BE (GM13154) and normals (AG10107) and (XP23BE - XPC (AG10033))
were obtained from the Human Genetic Mutant Cell Repository, Camden, NJ. XP10TA cells
were established at Tel Aviv University. XP161BE, XP164BE, XP139DC, and the XP-C strain,
XP108DC, were supplied by the Department of Environmental and Toxicologic Pathology,
Armed Forces Institute of Pathology, Washington, DC. XP3GO primary fibroblasts were
established at the Department of Dermatology, Georg-August-University, Goettingen,
Germany. XP1SE was obtained from Department of Dermatology and Cutaneous Biology
Research Institute, Yonsei University College of Medicine, Seoul, Korea. Normal skin primary
fibroblasts (AG4659, AG5186, AG13153, and AG13145) were obtained from the Human
Aging Cell Repository, Camden, NJ. Fibroblast cell lines were grown in DMEM (Invitrogen,
Grand Island, NY) containing 4mM glutamine and 10% fetal calf serum, as previously
described (Khan et al., 2004).
Host cell reactivation assay
To screen the UV sensitivity of the cells, we performed post-UV host cell reactivation assay
as described previously (Emmert et al., 2002). The pCMVLuc reporter gene plasmid (a
generous gift from M Hedayati and L Grossman, John Hopkins University, Baltimore, MD)
was used to measure post-UV host cell reactivation. A 200-ng weight of CsCl-purified
pCMVLuc, either 1,000 Jm−2 UV-irradiated or unirradiated, was transfected into 1.5×105
fibroblast cells per well using 4 μl of Lipofectamine (Invitrogen) in a total 1ml of OPTI-MEM
medium (Invitrogen) for 5 hours. After 48 hours of incubation, luciferase activity was measured
with a luminometer (Monolight 2010; Analytical Luminescence Laboratory, San Diego, CA)
using luciferase assay reagent (Promega, Madison, WI) according to the manufacturer’s
protocol. Relative luciferase activities are presented as a percentage of activities obtained with
UV-irradiated versus unirradiated control plasmids.
Semi-quantitative estimation of polη and polι protein expression
Polη and polι protein levels were assessed by IP followed by western blotting as described
previously (Thakur et al., 2001; Kannouche et al., 2003; Laposa et al., 2003; Tanioka et al.,
2007). Polι protein was detected using a rabbit polyclonal antibody directed against a keyhole
limpet hemocyanin-conjugated peptide corresponding to the extreme C-terminal 15 amino-
acid residues (AEWKRTGSDFHIGHK) of poli (Kannouche et al., 2002).
PCR amplification, sequencing of POLH and POLI, and measurement of POLH mRNA
DNA was isolated using DNAzol reagent as per vendor’s protocol (Invitrogen). Total
cytoplasmic RNA was isolated from cells by the RNA aqueous small-scale phenol-free total
RNA isolation kit (Ambion, Austin, TX) according to the vendor’s protocol. To sequence the
entire coding region and exon–intron junction sites of POLH and POLI genes, each exon and
the entire coding region were amplified using intronic and exonic primers (Table S1). The
primers were designed on the basis of the GenBank reference sequences (accession no.
NC_000006 for POLH genomic sequence; NM_006502 for POLH cDNA sequence; and
NC_000018 for POLI genomic sequence). RT-PCR amplification of the entire coding region
of POLH was performed using primers S0 (GATCCCTTCTCGGTTTCTCC) and AS24
(ATCCTACAGGCAAGCCTGAG) (Masutani et al., 1999b), with two PCR involving
denaturing at 94 °C for 1minute, 35 cycles of denaturing at 94 °C for 20 seconds, and annealing/
extension at 70 °C for 3minutes, followed by extension at 70 °C for 3 minutes. PCR products
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were sequenced by using the Thermo Sequenase II dye-terminator cycle sequencing Premix
Kit (Amersham Pharmacia, Piscataway, NJ). POLI sequence analysis was performed similarly
as described for POLH. Real-time quantitative RT-PCR for measurement of POLH mRNA
was performed with pairs of primers, where one primer spanned an exon–exon boundary as
described by Khan et al. (2002) (2006) (Table S1).
Mutations were described according to the recommendations of the Human Genome Variation
Society (den Dunnen and Antonarakis, 2000) (http://www.hgvs.org/mutnomen/) and the
nomenclature was checked using the mutalyzer website http://www.lovd.nl/mutalyzer/1.0.1/.
DNA sequence information analysis
The sequences of normal splice donor and acceptor sites of each exon and all of the sequences
with mutations we identified were scanned with the donor and acceptor individual information
weight matrices (Schneider, 1997a, b). This analysis can be performed on a web server, https://
splice.cmh.edu/. The normal sequences of splice donor and acceptor sites of each exon and
information contents are calculated and listed in Table S2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical appearance of XP-V patients
Family A: (a) XP31BE, 60 year Caucasian man had full-thickness skin removed from his face
as a teenager because of multiple skin cancers. This skin was replaced with sun-protected skin
from his abdomen and has been free of cancers ever since. He had BCC, SCC, and melanomas
on non-grafted skin of his head and upper extremities. Family C: (b) C-1, XP71TMA, 8-year-
old Turkish boy, had SCC. (c) C-2, XP70TMA, 17-year-old sister of XP71TMA, had SCC and
BCC. (d) C-3, XP98TMA, 26-year-old sister of XP71TMA, had a large SCC on her left cheek.
Family D: (e) D-1, XP91TMA, a 10-year-old Turkish man, had no skin cancers. (f) D-2,
XP92TMA, brother of XP91TMA, died at age 22 years of metastasis of the SCC on his lip.
Family F: (g) F-1, XP161BE, a 46-year-old Caucasian woman with multiple skin BCCs and
melanomas. (h) F-2, XP164BE, 52-year-old sister of XP161BE, had multiple BCCs, SCCs,
and melanomas. Family G: (i) XP3GO, a 30-year-old German man with multiple BCCs, SCCs,
and melanomas. Family I: (j) XP224BE, a 31-year-old Caucasian woman, had multiple BCCs
and melanomas.
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Figure 2. Post-UV host cell reactivation assay showing normal DNA repair in XP-V cells
UV-treated or control unirradiated luciferase containing plasmid was transfected into cells from
normal (AG5186) (light gray bar), XP-C (XP108DC) (dark gray bar), and putative XP-V
donors (XP31BE, XP38BE, XP164BE, XP70TMA, XP92TMA, XP3GO, XP224BE, and
XP10TA) (open bars). Two days later luciferase activity was measured. The relative luciferase
activity of the UV treated to the control plasmid reflects repair activity of the cells. The XP-C
cell had low activity and the putative XP-V cells had repair activity in the normal range. The
mean ± SEM of triplicate experiments is shown.
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Figure 3. Semi-quantitative estimation of polη and polι protein in XP and normal fibroblasts
Normal and putative XP-V cells were assayed by IP-Western blotting of whole-cell extracts.
(a) Polη protein and (b) polι protein.
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Figure 4. Sequence analysis of family A
(a) Genomic DNA of XP31BE shows change of G to C at exon 6 splice donor site (arrows).
There is a single curve in the uncloned DNA, indicating homozygous or hemizygous mutation.
(b) RT-PCR using RNA from XP31BE with forward primer C504F (in exon 5) and reverse
primer C892R (spanning the exon 8/7 junction) showed a single 388-bp band in normal cells
and two bands (arrows) at 284 and 346 bp in XP31BE cells. The diagram indicates deletion of
the entire 104 bp of exon 6 in the type-I splice variant and partial deletion (42 bp) of exon 6 in
the type-II splice variant. (c) PCR-RFLP assay for family A. The G-to-C mutation creates a
new DdeI restriction site. The gel shows genomic DNA from the father, XP31BE, mother, and
a normal donor. + Indicates DdeI treatment. The arrows indicate 63 and 54-bp bands of digested
DNA. * Indicates the normal-size band.
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Figure 5. Analysis of genomic DNA of families C and D
The C454T mutation in exon 4 creates a new DdeI restriction site. DNA from a normal donor,
affected siblings XP70TMA, XP71TMA, XP98TMA, and their mother (XPH95TMA) in
family C, and affected siblings XP91TMA and XP92TMA in family D were separated on 3%
agarose gel. + Indicates DNA digested with DdeI. The digested DNA showed two bands of 92
and 132 bp (arrows). * Indicates the normal-size band.
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Figure 6. Sequence analysis of families E and F
(a) Genomic DNA from XP38BE in family E shows an insertion of a G in exon 10. There is
a single sequence following the insertion indicating that the DNA is homozygous or
hemizygous for this frameshift mutation. (b) PCR-RFLP assay of family E. The insertion of
G creates a new BsII site in the genomic DNA. Genomic DNA from a normal donor, patients
XP38BE, XP39BE, and their mother, XPH253BE, was run on a gel. + Indicates BsII treatment.
The 105 and 248-bp bands in the digested DNA are indicated by arrows. * Indicates the normal-
size band. (c) PCR-RFLP analysis for family F. Genomic DNA from XP164BE, XP161BE,
the husband, son, daughter, mother, and father of XP161BE was run on a gel. + Indicates
BsII treatment. The 105 and 248-bp bands in the digested DNA are indicated by arrows. *
Indicates the normal size band.
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Figure 7. Mutation spectrum and predicted proteins in XP-V cells
The top line shows the 11 exons of POLH genomic sequence on chromosome 6 as filled
rectangles. The location of frameshift, nonsense, and missense mutations in each allele for the
cells studied is shown above the line and the splice site mutations are shown below the line.
The second line shows the mRNA with the ATG initiation codon in exon 2 and the TAG stop
codon in exon 11. The 713-amino-acid pol-η protein is shown in the third line. The N-terminal
400 amino acids are highly conserved in Y-family polymerases, and contain the catalytic
domain of the polymerase. There is a nuclear localization signal located at amino acids 682–
698 (NLS). The C-terminal region from amino acids 628–662 contains a C2H2 zinc finger that
is involved in DNA-binding ubiquitin. A PCNA-binding site is located at the extreme C-
terminus of the protein. The bottom portion of the figure shows the predicted size of the protein
from each allele or splice variant form from the XP-V patients and the description of the
mutation at the cDNA and protein level. PCNA, proliferating-cell nuclear antigen.
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